Study of ABT-301 plus tislelizumab and bevacizumab for advanced colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug combination (ABT-301, tislelizumab, and bevacizumab) for people with a specific type of advanced colorectal cancer that has not responded to at least two prior treatments. It aims to see if this combination can help shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have advanced colorectal cancer that is pMMR/non-MSI-H (a specific marker) and has not improved after at least two prior treatments.
- You must have a tumor sample from the past 5 years (or a new biopsy) available for testing.
- You must be able to do daily activities without help (ECOG score 0 or 1).
- Your blood counts, kidney, and liver function must be within certain limits, as shown by recent lab tests.
- You cannot have active autoimmune disease, serious heart problems, or recent major surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a combination of three drugs — an immunotherapy (sintilimab), a blood vessel growth blocker (bevacizumab), and a chemotherapy helper (decitabine) — for people with advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if this combination can help control the cancer when standard options have failed.
This trial tests a combination of oral chemotherapy, targeted therapy, and immunotherapy, with or without radiation, for people with advanced colorectal cancer that hasn't responded to at least two prior treatments. The goal is to see if this approach can help shrink tumors or slow the disease.
This study tests a combination of two drugs (bevacizumab and adebrelimab) for people with a specific type of advanced colorectal cancer that has not responded to standard treatments. It aims to see if this combination can help control the cancer and improve outcomes.
This trial tests a new drug combination for colorectal cancer that has not responded to other treatments. It compares the new drug with a standard treatment to see which is more effective.
This trial tests whether adding an experimental drug (INCA33890) to standard chemotherapy and bevacizumab helps people with a certain type of advanced colorectal cancer. It is for those whose cancer has spread and has not been treated yet with systemic therapy.
This trial tests a new drug (TQB2930) combined with chemotherapy, with or without another drug called bevacizumab, for people whose colorectal cancer has spread or cannot be removed by surgery and has a specific protein called HER2. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Hear when a new Colorectal Cancer (Diagnosis) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.